ZBD(SH:603567) Hua Xia Shi Bao·2025-05-06 05:44Core Viewpoint - Zhenbaojiao (603567.SH) demonstrates robust growth in 2024, with a notable 20.23% year-on-year increase in revenue, particularly in its pharmaceutical manufacturing core business, supported by a diversified product matrix and an innovative R&D system [1] Group 1: Business Performance - The company has established a product matrix covering major categories such as cardiovascular, antiviral, respiratory, and pediatric medicine, showcasing its strength in traditional Chinese medicine [1][2] - In 2024, Zhenbaojiao aims to seize market opportunities by deepening its presence in various terminal markets and gradually building a core product group focused on key therapeutic areas [2] Group 2: Market Potential - The market scale for Zhenbaojiao's core products is significant, with annual market sizes exceeding 100 billion yuan for both cardiovascular and respiratory traditional Chinese medicine [3] - Zhenbaojiao's products, such as Xuefu Zhuyu Capsule and Shuxuening Injection, rank highly in market share within their respective therapeutic areas, indicating strong competitive positioning [3] Group 3: Innovation and R&D - The company is committed to enhancing product competitiveness through R&D and acquisitions, focusing on expanding its product line and improving product quality [4] - Zhenbaojiao is actively engaged in research and re-evaluation of existing products, including clinical efficacy and safety assessments, and is advancing innovative drug projects [4] Group 4: Mergers and Acquisitions - The company has completed the acquisition of 23 products, including Dan Ning Pian and An Gong Niu Huang Wan, to enrich its product pipeline and enhance market competitiveness [5] Group 5: Marketing and Distribution - Zhenbaojiao has established a comprehensive marketing network across over 30 provinces in China, focusing on cardiovascular and respiratory diseases while expanding into pediatric and digestive health markets [7] - The company is actively participating in centralized procurement projects, having successfully selected 14 core product specifications for national and provincial procurement initiatives [7] Group 6: Trade and Strategic Development - The company is optimizing its national trading strategy for traditional Chinese medicine, establishing a network of offices in major production areas to enhance supply chain efficiency [8] - Zhenbaojiao aims to leverage its advantages in market share, R&D innovation, and marketing systems to solidify its leading position in the traditional Chinese medicine industry [8]